Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Simvastatin is a lipid-lowering agent belonging to the class of HMG-CoA reductase inhibitors, commonly known as statins. It is used in combination with diet, weight loss, and exercise to reduce elevated levels of low-density lipoprotein (LDL) cholesterol ("bad" cholesterol), total cholesterol, apolipoprotein B, non-high-density lipoprotein cholesterol (non-HDL-C), and triglycerides in the blood. Simultaneously, it increases high-density lipoprotein (HDL) cholesterol ("good" cholesterol). The drug works by competitively inhibiting HMG-CoA reductase—the enzyme responsible for catalyzing the rate-limiting step in hepatic cholesterol biosynthesis—thereby reducing endogenous production of cholesterol. This leads to upregulation of hepatic LDL receptors and increased clearance of LDL from circulation. Simvastatin is indicated for lowering cardiovascular risk by preventing heart attacks, strokes, angina, and other complications associated with atherosclerosis in adults and children aged 10 years or older with familial heterozygous hypercholesterolemia.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on simvastatin.